Objectives: Information has been collected from positron emission tomography/magnetic resonance imaging (PET/MRI) operational sites to identify its present and future applications. This may help to focus discussions on common interests of the PET/MRI community. Methods: A webbased survey of PET/MRI users was conducted from June to October 2015. The survey was composed of 26 questions related to (A) the PET/MRI center, (B) present utilization and imaging protocols and (C) perspectives on key applications. Results: Responses were collected from 39 international sites that operated PET/MRI for a median of 30 months (range, 2 to 62 months). Most installations were located in public institutions with an academic focus (n=26, 67%). Systems were primarily operated by Nuclear Medicine Departments (n=13, 33%), jointly by Nuclear Medicine and Radiology (n=11, 28%), and Radiology only (n=10, 26%). PET/MRI operation was equally focused on clinic routine and research (47% vs. 45% of sites respectively). Sites reported a strong focus on oncology (76% of research and 88% of clinical applications). Other applications included neurology (9% clinical, 12% research) and cardiology (3% clinical, 6% research). Perceived superiority over positron emission tomography/computed tomography (PET/CT) was identified as the strongest driver for clinical adoption. Over half the operators expect PET/MRI to excel in clinical routine within three to five years. Emerging key applications for future PET/MRI use were cardiovascular disease and imaging of inflammation. Conclusion: An international survey of early PET/MR adopters reveals a mixed utilization of this combined imaging modality with a focus on oncology. The future of PET/MRI is seen in expanded application for oncology, neurology, but also cardiovascular disease and inflammation.
INTRODUCTION
international PET/MRI users was conducted to record and document such current utilization patterns in clinical routine and research.
by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from
METHODS

Concept
A survey of international PET/MRI users was designed in February 2015 to collect data on existing PET/MRI operations worldwide and to review PET/MRI protocol variations. The idea for this data collection originated from discussions during the recent PET/MRI workshop in Tübingen (16) and a subsequent review of the international survey on PET/CT operations conducted a few years earlier (17). As in this previous study we decided to benefit from the easy, rapid and widespread distribution of web-based questionnaires. Similar to our previous study, we prepared our survey in line with recent recommendations on the structure of surveys that -in theory -help to maximize response rates; this included a personal introductory statement, the offer to make results public, the use of simple headers and textual representation of response categories, and the provision of a relatively short deadline including multiple reminders.
Survey
The electronic questionnaire consisted of 26 questions (see supplemental material section) that could be answered in about 20 minutes. Questions, developed by imaging experts with extensive experience in PET/CT and PET/MRI imaging addressed three issues: (A) the operation of the PET/MRI centers (n=9), (B) current applications and imaging protocols (n=14) and (C) perspectives on future key applications (n=3). Question types were dichotomous, single choice, 
Statistical Analysis
Responses were collected anonymously and tabulated for each question. We report total number of response per answer option, proportion of response per respective answer option in percent, rank of answer options, or median (range) for quantitative response. Free text response for key applications (questions 23 and 24) was summarized by field of application into five categories (Cardiovascular, Pediatric, Other, Neurology, Oncology) with respective subcategories.
RESULTS
A total of 39 responses were collected from 69 active PET/MRI users between June and October of 2015. All responses were satisfactory in quality and quantity and, therefore, the overall response rate was 57%.
Demographics -PET/MRI Center (Questions 1-9)
The 39 responding sites were located in Europe (62%), North America (23%), and Asia Pacific (16%) (Fig. 1A) . Responding sites operated PET/MR systems from Siemens Healthcare (77%), Philips Healthcare (13%), and GE Healthcare (10%) (Fig. 1B) , which corresponded well to the known market shares of these companies at time of the survey (72%, 14% and 14%, respectively).
The number of active PET/MRI sites grew continuously since 2010 with an average number of 8 sites becoming operational each year (Fig. 1C) . Responding sites had operated PET/MRI for a median of 30 months (range, 2 to 62 months) and 23 of 39 (59%) sites had PET/MRI experience for ≥2 years. Median number of staff was lower for public (n=9) versus private (n=15) institutions, and for Joint, Nuclear Medicine, or Other Departments (n=10) as compared to Radiology Departments (n=13).
Median number of employees was similar in institutions with PET/MRI interpretation by radiologists or nuclear medicine physicians only (n=11) when compared to the entire group (n=10). In total, 44706 patients underwent a PET/MRI at the responding sites, which corresponds to an average throughput of about 8 (max. 38) patients per week. This average number, derived from the total number of patients scanned divided by the number of weeks of operation for each site, however, was lower than the present throughput reported by the sites at 12 (max. 35) patients per week.
Present Applications (Questions
Variations in Imaging Protocols (Questions 14, 17-22)
Imaging protocols vary widely across active PET/MRI sites ( Table 2 ). Since no PET/MRI standard or guidelines have been published, survey questions regarding typical imaging protocols by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from were phrased more generically. Typical cardiology and oncology imaging protocols were reported to take a median of 60 min, with 30 min minimum and 100 min to 120 min maximum. A typical neurology imaging protocol was somewhat shorter with a reported median of 45 min (range, 10 min to 120 min).
The most frequently used PET probe across all categories and applications was 18 F-FDG. 13 N-NH 3 (ranked #2), 18 F-FET (ranked #3), and prostate-specific membrane antigen (PSMA) ligands (ranked #3) were also used frequently.
MR protocols were heterogeneous with a certain degree of overlap (Supplemental Table 1 ).
All reported neurology MRI protocols included diffusion weighted imaging (DWI) and/or fluid attenuation inversion recovery in addition to T1-and T2-acquisition. MR protocols for oncology imaging frequently included Dixon (5/8), DWI (4/8), and volumetric interpolated breath-hold examination (VIBE; 3/8) sequences. About two thirds of the sites (25/39, 64%), foremost those from the private sector (80%) and those within Radiology, Radiation Therapy, or Research Departments (70% -80%), performed MRI-only protocols in addition to PET/MRI imaging (Table 1) . Most patients would, in the user's perspective (25 of 39, 64%), have undergone MRI and PET/CT in case PET/MRI was not available.
Present and future Key Applications (Questions 23-24)
Participants named up to three key applications for present and future use of PET/MRI (Fig.   3 ). Oncology (n=24) and neurology (n=13) were most frequently mentioned for present key application, followed by pediatric (n=4) and other (n=7) imaging. General oncology and prostate cancer were most prevalent oncology indications; general neurology and dementia imaging were the most prevalent neurology indications.
None of the participants listed cardiovascular disease at present, however, seven participants included cardiovascular imaging, e.g. for diagnosis of cardiac fibrosis, atherosclerosis, or vasculitis, as future key application of PET/MRI. Furthermore, imaging inflammation was by Third, the interpretation of PET/MRI images is more challenging than that of PET/CT studies. This was reflected in our survey by the fact that interpretation was jointly performed by radiologists and Nuclear Medicine physicians at more than 80% of PET/MRI sites versus only approx. 40% of PET/CT sites in our previous survey (17).
PET/MRI was performed equally often for clinic and research. Oncology was the dominant application of present clinical and research use (88 and 76%; respectively). Cancers that were imaged frequently with stand-alone MRI before the availability of PET/MRI (i.e. patients with prostate cancer, brain tumors, and head & neck cancer) were listed as the top three indications.
The focus on these tumor entities, for which MRI may be considered an anatomic modality-ofchoice, is reasonable if cost-effectiveness is demonstrated and patient comfort is acceptable.
However, this ranking of indications also underlines a current lack of definite new indications for fully-integrated (8,9) PET/MR imaging.
The survey revealed a low current or future proportion of neurologic and cardiovascular PET/MRI examinations. This is surprising as these indications were frequently named as key future applications (2, 20) . Cardiovascular disease was not mentioned as a key present indication by any of the participants; pediatric imaging was named as a key application by only 4/39 sites and was even less frequently mentioned as a key future indication. This is surprising, given the frequently publicized radiation concerns of the pediatric medical community (21,22). However, imaging of by on August 28, 2017. For personal use only. jnm.snmjournals.org Downloaded from inflammation and cardiovascular diseases was voted first and second most anticipated future indication.
In general, the current survey suggests that both current and future applications might evolve around oncologic entities and questions. Given the high utilization of PET/CT and its acceptable costs in cancer (23) it remains questionable whether this will result in dramatic increases in PET/MRI utilization in cancer patients. However PET/MRI is still at the level of early adoption with a number of unsolved technical, regulatory and funding issues. Utilization patterns of the current respondents might therefore not be representative for the PET/MRI community of the future. 
